BRIDGEWATER, N.J., Feb. 16, 2021 /PRNewswire/ -- Insmed
Incorporated (Nasdaq: INSM), a global biopharmaceutical company on
a mission to transform the lives of patients with serious and rare
diseases, today announced that it will release topline data from
its Phase 1 healthy volunteer trial of treprostinil palmitil
inhalation powder (TPIP) on Friday, February
19, 2021.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Friday,
February 19, 2021 to discuss findings and provide an
update.
Shareholders and other interested parties may participate in the
conference call by dialing (833) 340-0284 (domestic) or (236)
712-2425 (international) and referencing conference ID number
1963113. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through March
21, 2021 by dialing (800) 585-8367 (domestic) or (416)
621-4642 (international) and referencing conference ID number
1963113. A webcast of the call will also be archived for 90 days
under the Investor Relations section of the company's website at
www.insmed.com.
About TPIP
Treprostinil palmitil inhalation powder (TPIP) is a dry powder
formulation of treprostinil palmitil, a treprostinil prodrug
consisting of treprostinil linked by an ester bond to a 16-carbon
chain. Developed entirely in Insmed's laboratories, TPIP is a
potentially highly differentiated prostanoid being evaluated for
the treatment of patients with pulmonary arterial hypertension
(PAH) and other rare and serious pulmonary disorders. TPIP is
administered in a capsule-based inhalation device.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United States and the European
Union to treat a chronic, debilitating lung disease. The Company is
also progressing a robust pipeline of investigational therapies
targeting areas of serious unmet need, including
neutrophil-mediated inflammatory diseases and rare pulmonary
disorders. Insmed is headquartered in Bridgewater,
New Jersey, with a growing
footprint across Europe and in Japan. For more
information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-conference-call-to-discuss-topline-data-from-treprostinil-palmitil-inhalation-powder-phase-1-study-301228316.html
SOURCE Insmed Incorporated